Fig. 4

Association of TP53 and ARID1A mutations with the therapeutic effect of CAR-T cell therapy. Comparison of the incidence of (a) TP53 mutations and (d) ARID1A mutations in the CAR-T cell response group (left) and CAR-T cell no response group (right). Wt, wild-type ARID1A; Mut, ARID1A mutation. Comparison of variant allele frequencies (VAFs) among (b) TP53 and (e) ARID1A mutations in the CAR-T cell response group (left, green box) and CAR-T cell no response group (right, orange box). (c) Patients with mutations (MUT) in TP53 (red line) showed worse survival than patients with wild-type (Wt) TP53 (blue line). (f). The survival probability was significantly lower in patients with ARID1A mutations (Mut, red line) than in patients with wild-type ARID1A (Wt, blue line) (p = 0.01)